Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with Bayer Schering Pharma, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with Bayer Schering Pharma, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by Bayer Schering Pharma. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborat
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article ... cared for in nursing homes and assisted living facilities are receiving insufficient care that ... in which her father was at one point close to death, not because of ...
(Date:9/4/2015)... CO (PRWEB) , ... September 04, 2015 , ... Mile ... the ways in which a lack of funding for sidewalks, bike paths, and other ... the report, while the Denver region spends billions of dollars to expand public transit, ...
(Date:9/4/2015)... ... ... After wearing the same uniforms for six seasons, the Sprayberry High School girls ... the team, the Jones Agency, a locally owned insurance firm that serves communities in ... uniforms. , As is so often the case with high school and many school-related ...
(Date:9/4/2015)... CA (PRWEB) , ... September 04, 2015 , ... ... announces that CEREC technology is now available at CitiDent. CEREC is a newer ... In addition to saving time for patients by eliminating the need for multiple ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is ... 9 nationwide by Doximity. Faculty, residents and staff are honored to have contributed ... the quality of our ophthalmology residency program. Our faculty places a high priority on ...
Breaking Medicine News(10 mins):Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3
... The 2010 Annual Meeting & OTO EXPO of the ... (AAO-HNSF), the largest meeting of ear, nose, and throat doctors ... MA. , Featuring more than 305 scientific research sessions, ... the annual meeting is a unique opportunity for journalists from ...
... graduate student Brian Zikmund-Fisher was forced into the toughest choice ... few years or endure a bone marrow transplant that could ... now an assistant professor at the University of Michigan School ... After nine months of blood transfusions, a bone marrow match ...
... be a promising personalized treatment method for approximately 45 ... c-Met-positive tumors, according to study results presented at the ... Therapeutic Development. HCC is the most common ... receptor for hepatocyte growth factor that appears to drive ...
... (September 28, 2010) -- A new disposable device based ... cancer patients who are candidates for therapy with the ... American Institute of Physics, journal Biomicrofluidics . ... levels of the protein HER2 (the tyrosine kinase human ...
... recent years, several guidelines in the treatment of posttraumatic ... guidelines across the health sphere are very important in ... high level of consensus on these guidelines among practitioners, ... among providers, patients, and purchasers of mental health services ...
... 28, 2010 -- Individual cancer-causing mutations have a minute ... division by just 0.4 percent on average, according to ... Hopkins University, and other institutions. Their research, appearing ... Academy of Sciences , reinforces that cancer is the ...
Cached Medicine News:Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 2Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 3Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 4Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 5Health News:Doctors need to help patients prepare better for health decisions 2Health News:Doctors need to help patients prepare better for health decisions 3Health News:New device for identifying aggressive breast cancers 2Health News:New device for identifying aggressive breast cancers 3Health News:Leading practitioners recommend global PTSD treatment guidelines 2Health News:Individual mutations are very slow to promote tumor growth 2
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
... Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years ... ... ... ...
The Empore 96 well plate vacuum manifold comes complete with waste tray, gasket and shims, may be used as a stand-alone or with 96-well automation....
For regulating sample flow rate when using the QIAvac 24 Plus;...
Medicine Products: